FeesSafety
Pluang+

Escalade Q3 2026 net income rises to $6.7M despite 3.2% sales drop, driven by margin gains and acquisitions.

Company Fundamentals
29 Oct 2026, 13:00 WIB
PRNewsWire
View Source
Bullish
Escalade Q3 2026 net income rises to $6.7M despite 3.2% sales drop, driven by margin gains and acquisitions.

Escalade reported a 3.2% decline in net sales to $65.6 million for Q3 2026 but improved gross margin by 123 basis points to 29.4%, boosting net income to $6.7 million or $0.48 per share, up from $5.6 million a year earlier. The sales drop was mainly due to lower demand in basketball and indoor games, offset by growth in archery and outdoor categories, aided by the Gold Tip acquisition. Strong cash flow and reduced debt strengthened the company's financial position. Management expects continued market challenges but anticipates growth from new products and acquisitions in 2027.

Escalade's third quarter 2026 results provide context for market activity in the Consumer Cyclical sector. For readers following this sector, here is Pluang's market snapshot as of Oct 29, 2026 17:11 WIB: Among 134 priced US stocks, 87 rose and 36 fell today. Notable movers include Burlington Stores Inc (BURL) at USD 240.46 with a 1-day change of +2.75% and 100% buy order activity, D R Horton Inc (DHI) at USD 139.41 down 2.51%, and Yum! Brands, Inc. (YUM) at USD 153.43 up 2.18% with a typical hold time of 134 days on Pluang.

More News

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

NCH performs US first tricuspid valve repair with PASCAL Precision system after FDA approval

Naples Comprehensive Health (NCH) has completed the first tricuspid valve repair in the US using the PASCAL Precision system following FDA approval. This minimally invasive catheter-based procedure offers a new treatment option for patients with seve...

Market News
Bullish
15 minutes ago
Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore to present Phase 1 data on brenetafusp and KIMMTRAK combo for metastatic uveal melanoma at SITC 2026

Immunocore Holdings will present Phase 1/2 clinical trial data for brenetafusp alone and combined with KIMMTRAK in treating metastatic uveal melanoma at the 2026 Society for Immunotherapy of Cancer meeting. This trial evaluates safety and efficacy in...

Company Fundamentals
Bullish
15 minutes ago
Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC expand partnership to support neurodivergent youth in Massachusetts sports.

Collegium Pharmaceutical and Boston Legacy FC have extended their partnership to include youth coach training, an annual Sports for All Summit, and sensory inclusion programs aimed at supporting neurodivergent children, especially those with ADHD, in...

Others
Bullish
1 hour ago
Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks to attend Deutsche Bank Global Space and Defense Tech Summit in NYC

Gilat Satellite Networks announced that its CEO Adi Sfadia and CFO Gil Benyamini will attend the Deutsche Bank Global Space and Defense Tech Summit on November 18, 2026, in New York City. The event will feature one-on-one and group meetings, providin...

Market News
Neutral
1 hour ago
Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex buys Wind2 to boost UK wind energy projects by 350 MW, expanding its renewable footprint.

Boralex Inc. has acquired Wind2, a UK-based renewable energy developer with about 350 MW of advanced wind projects across Scotland, England, and Wales. This acquisition strengthens Boralex's presence and capabilities in the UK, aligning with its stra...

Company Fundamentals
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App